Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037

被引：0
|
作者：
Hamid, O. [1 ]
Gajewski, T. F. [2 ,3 ]
Frankel, A. E. [4 ]
Bauer, T. M. [5 ]
Olszanski, A. J. [6 ]
Luke, J. J. [7 ]
Balmanoukian, A. S. [1 ]
Schmidt, E. V. [8 ]
Sharkey, B. [9 ]
Maleski, J. [9 ]
Jones, M. J. [9 ]
Gangadhar, T. C. [10 ]
机构：
[1] Angeles Clin & Res Inst, Res, Los Angeles, CA USA
[2] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Internal Med, Dallas, TX 75390 USA
[5] Sarah Cannon Res Inst Tennessee Oncol, Drug Dev Unit, Nashville, TN USA
[6] Fox Chase Canc Ctr, Dept Med Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[7] Univ Chicago, Hematol Oncol, Chicago, IL 60637 USA
[8] Merck & Co Inc, Oncol Clin Res, Kenilworth, NJ USA
[9] Incyte Corp, Drug Dev, Wilmington, DE USA
[10] Univ Penn, Abramson Canc Ctr, Hematol Oncol Div, Med, Philadelphia, PA 19104 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1214O
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC)
    Kudo, Masatoshi
    Finn, Richard S.
    Edeline, Julien
    Cattan, Stephane
    Ogasawara, Sadahisa
    Palmer, Daniel H.
    Verslype, Chris
    Zagonel, Vittorina
    Fartoux, Laetitia
    Vogel, Arndt
    Sarker, Debashis
    Verset, Gontran
    Chan, Stephen Lam
    Knox, Jennifer J.
    Daniele, Bruno
    Gurary, Ellen B.
    Siegel, Abby B.
    Jain, Lokesh
    Cheng, Ann-Lii
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [42] Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
    Koshkin, Vadim S.
    Sonpavde, Guru P.
    Hwang, Clara
    Mellado, Begona
    Tomlinson, Gareth
    Shimura, Masashi
    Chisamore, Michael Jon
    Gil, Maciej
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [43] PD-L1 EXPRESSION AND EFFICACY IN PATIENTS TREATED WITH PEMBROLIZUMAB VS IPILIMUMAB FOR ADVANCED MELANOMA IN KEYNOTE-006
    Carlino, M.
    Emancipator, K.
    Ibrahim, N.
    Zhou, H.
    Schadendorf, D.
    Ribas, A.
    Gonzalez, R.
    Hoeller, C.
    Bar-Sela, G.
    Barrow, C.
    Chao, D.
    Wolter, P.
    Berking, C.
    Straume, O.
    Berrocal, A.
    Holgado, E.
    Gangadhar, T. C.
    Weiss, G.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 44 - 44
  • [44] Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph P.
    Riedell, Peter A.
    Fleury, Isabelle
    Du, Yan
    Han, Xia
    Pearson, David
    Redondo, Santiago
    Waller, Edmund K.
    BLOOD ADVANCES, 2023, 7 (11) : 2283 - 2286
  • [45] Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
    Cho, Byoung Chul
    Brana, Irene
    Cirauqui, Beatriz
    Aksoy, Sercan
    Couture, Felix
    Hong, Ruey-Long
    Miller Jr, Wilson H.
    Chaves-Conde, Manuel
    Teixeira, Margarida
    Leopold, Lance
    Munteanu, Mihaela
    Ge, Joy Yang
    Swaby, Ramona F.
    Hughes, Brett G. M.
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [46] Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
    Bang, Y. J.
    Doi, T.
    De Braud, F.
    Piha-Paul, S.
    Hollebecque, A.
    Razak, A. R. Abdul
    Lin, C. C.
    Ott, P. A.
    He, A. R.
    Yuan, S. S.
    Koshiji, M.
    Lam, B.
    Aggarwal, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S112 - S112
  • [47] Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
    Shah, Manish A.
    Kojima, Takashi
    Hochhauser, Daniel
    Enzinger, Peter
    Raimbourg, Judith
    Hollebecque, Antoine
    Lordick, Florian
    Kim, Sung-Bae
    Tajika, Masahiro
    Kim, Heung Tae
    Lockhart, A. Craig
    Arkenau, Hendrik-Tobias
    El-Hajbi, Farid
    Gupta, Mukul
    Pfeiffer, Per
    Liu, Qi
    Lunceford, Jared
    Kang, S. Peter
    Bhagia, Pooja
    Kato, Ken
    JAMA ONCOLOGY, 2019, 5 (04) : 546 - 550
  • [48] Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study
    Chung, Hyun Cheol
    Schellens, Jan H. M.
    Delord, Jean-Pierre
    Perets, Ruth
    Italiano, Antoine
    Shapira-Frommer, Ronnie
    Manzuk, Lyudmila
    Piha-Paul, Sarina Anne
    Wang, Jiangdian
    Zeigenfuss, Susan
    Pruitt, Scott K.
    Marabelle, Aurelien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
    Fuchs, Charles S.
    Doi, Toshihiko
    Jang, Raymond W.
    Muro, Kei
    Satoh, Taroh
    Machado, Manuela
    Sun, Weijing
    Jalal, Shadia I.
    Shah, Manish A.
    Metges, Jean-Phillipe
    Garrido, Marcelo
    Golan, Talia
    Mandala, Mario
    Wainberg, Zev A.
    Catenacci, Daniel V.
    Ohtsu, Atsushi
    Shitara, Kohei
    Geva, Ravit
    Bleeker, Jonathan
    Ko, Andrew H.
    Ku, Geoffrey
    Philip, Philip
    Enzinger, Peter C.
    Bang, Yung-Jue
    Levitan, Diane
    Wang, Jiangdian
    Rosales, Minori
    Dalal, Rita P.
    Yoon, Harry H.
    JAMA ONCOLOGY, 2018, 4 (05)
  • [50] Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
    Gibney, G.
    Hamid, O.
    Lutzky, J.
    Olszanski, A.
    Gangadhar, T.
    Gajewski, T.
    Chmielowski, B.
    Hanks, B.
    Boasberg, P.
    Zhao, Y.
    Newton, R.
    Bowman, J.
    Maleski, J.
    Leopold, L.
    Weber, J. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S106 - S107
12345